The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index; 102 of the 170 sources its claims cite were checked for support.
Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies
Open accessAbstract
PURPOSE OF REVIEW: The goal of this review is to evaluate the evolving role of triglycerides (TGs) and TG-rich lipoproteins (TRLs) in cardiovascular disease (CVD) risk and prevention. We examine the mechanistic rationale, genetic and epidemiological evidence, and therapeutic potential of targeting TGs in residual risk reduction, particularly in high-risk populations. RECENT FINDINGS: Emerging data from Mendelian randomization studies and large clinical cohorts support a causal link between elevated remnant lipoproteins and atherosclerotic CVD, in which apolipoprotein B may be the principal driver. Although traditional triglyceride-lowering agents have produced mixed results on cardiovascular outcomes, emerging therapies-such as ApoC-III and ANGPTL3 inhibitors-show robust lipid-lowering effects, while selective PPAR modulators have thus far not demonstrated cardiovascular benefit. However, outcome data remain limited. Residual CVD risk persists despite aggressive LDL-C reduction, especially in patients with diabetes, metabolic syndrome, or chronic kidney disease. Selective TG-lowering strategies targeting TRLs-especially those that decrease apolipoprotein B-may provide clinical benefit in high-risk phenotypes. Ongoing trials will clarify whether these promising agents confer meaningful cardiovascular protection and warrant integration into future guidelines.
Overview
CoChat Summary
TL;DR
This narrative review argues that triglycerides and triglyceride-rich lipoproteins are causally related to residual cardiovascular risk, especially when apoB-containing remnants remain elevated despite LDL-C lowering. It concludes that existing triglyceride-lowering drugs have mixed outcome data, while newer apoC-III and ANGPTL3-targeted therapies are promising but still need definitive cardiovascular outcomes evidence.
Key findings
- Mendelian randomization and large cohort data support a causal link between elevated remnant lipoproteins and atherosclerotic CVD; the paper states that apoB may be the principal driver of this risk.
- In genetic studies, APOC3 loss-of-function variants are associated with a 40–50% lower risk of ischemic cardiovascular events, and ANGPTL4 inactivating variants with up to a 19% lower risk of CAD.
- Volanesorsen lowered triglycerides by ~77% in the phase III APPROACH trial in familial chylomicronemia syndrome, and in COMPASS it reduced triglycerides by ~71%; olezarsen phase 2/3 and phase 3 data showed triglyceride reductions of ~60%.
- Pemafibrate in PROMINENT reduced triglycerides by –26.2% but did not reduce MACE; by contrast, REDUCE-IT with icosapent ethyl reported a 25% reduction in MACE and a 26% reduction in the key secondary endpoint over 4.9 years in over 8,000 high-risk patients.
Methods
- Narrative review of triglyceride metabolism, epidemiology, genetics, imaging, and therapies for cardiovascular disease prevention.
- Synthesizes evidence from Mendelian randomization studies, large observational cohorts, and randomized clinical trials across statins, omega-3 fatty acids, fibrates/PPAR-α modulators, apoC-III inhibitors, and ANGPTL3 inhibitors.
- Main analysis is qualitative and comparative, emphasizing mechanistic rationale and whether outcome benefits track triglyceride lowering versus apoB reduction.
Limitations
- The paper explicitly states that outcome data remain limited for emerging therapies and that ongoing trials are needed to clarify cardiovascular benefit.
- It notes that traditional triglyceride-lowering agents have produced mixed results on cardiovascular outcomes.
- Evident from the text: this is a review, not a new primary study, so it does not present a single original dataset or meta-analytic effect estimate (not stated in the paper).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 General recommendations on lifestyle modifications and identifying secondary causes of hypertriglyceridemia. ASCVD- atherosclerotic cardiovascular disease, TG- triglyceride, wk- week §- consider referral to registered dietician for tailored dietary counseling. Figure created with data from the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia [65]. Figures created in BioRender. Mathai, S. (2025)https://BioRender.com/k3ux653](https://figures.cochat.ai/paper-figures/90e9b8a1c6d94330b782c564124d7506/targeting-triglycerides-in-cardiovascular-disease-prevention-evidence-mechanisms-figure-2.jpg)
![Fig. 3 Phenotypic approach for management of hypertriglyceridemia. ASCVD– atherosclerotic cardiovascular disease, DM- diabetes mellitus, IPE- Icosapent ethyl, LDL-C – low density lipoprotein cholesterol, TG- triglyceride. Figure created with data from the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia [65]. Figures created in BioRender. Mathai, S. (2025)https://BioRender.com/k3ux653](https://figures.cochat.ai/paper-figures/58908afd04bd474c9dcb2e7599dec868/targeting-triglycerides-in-cardiovascular-disease-prevention-evidence-mechanisms-figure-3.jpg)
Verification
Claims the paper makes
62 Valid · 6 Not valid · 36 Not checked · 25 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“From this perspective, triglycerides chiefly index TRL particle burden rather than act as an independent atherogen, and causal inferences often attenuate when apoB is accounted for in multivariable genetic analyses [2].”
§ Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies > Introduction > TG Metabolism and Pathophysiology
What the sources say
- Supportedcites [2] Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062. source
The Results section (‘Appraisal of LDL cholesterol, triglycerides, and apolipoprotein B’; page unavailable) reports that, in multivariable MR accounting for apoB, the triglyceride estimate weakened substantially and the LDL-cholesterol estimate reversed; only apoB retained a robust effect. This supports the attributed point about attenuation, without implying that triglycerides had no residual association. (LLM, conf=0.93)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“At the same time, it is important to recognize that apoB remains the most informative single summary measure of atherogenic risk, as LDL apoB numerically dominates total apoB in most individuals; accordingly, the benefits of lipid-lowering therapy appear to correlate more closely with reductions in apoB (particle number) than with triglyceride lowering alone [2, 18, 19].”
§ Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies > Introduction > TG Metabolism and Pathophysiology
What the sources say
- Supportedcites [2] Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062. source
The Discussion (page not provided) says lipid-modifying therapies should focus on reducing atherogenic particle number, measured by apoB, rather than triglycerides. It also identifies apoB as a surrogate for predicting the expected reduction in coronary heart disease risk from a therapy, supporting the claim's qualified comparison. (LLM, conf=0.92)
- Supportedcites [18] Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287–95. source
The Introduction says fibrates can markedly lower triglycerides yet fail to consistently produce clinical benefit when they make only modest changes in total apoB. It concludes that the pattern of benefit is consistent with benefit depending on apoB reduction, supporting the citing sentence’s hedged comparison. (LLM, conf=0.90)
- Partly supportedcites [19] Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, et al. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022;146:657–72. sourceExperimental — accuracy not yet measured
The Results (page not provided) report greater alirocumab treatment benefit at lower achieved apoB levels, and the Discussion links lower achieved apoB with lower cardiovascular risk after acute coronary syndrome. The paper does not compare that association with triglyceride lowering alone, and its analysis concerns achieved apoB levels rather than directly comparing reductions in the two measures. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have been further corroborated in studies examining ANGPTL4 and LPL variants, all reinforcing the concept that enhanced clearance of TRLs and their remnants mitigates ASCVD risk [27].”
§ Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies > Introduction > Genetic and Population-Level Evidence
What the sources say
- Partly supportedcites [27] Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52. sourceExperimental — accuracy not yet measured
The discussion passage labelled Abstract (page not supplied) says that greater LPL activity lowers triglycerides and that an LPL gain-of-function variant is associated with lower CAD risk. It also describes remnant particles as potentially pro-atherogenic. The copy does not report ANGPTL4-variant findings or establish that enhanced clearance of TRLs and their remnants is the mechanism reducing risk. (LLM, conf=0.85)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“EVAPORATE offered early mechanistic evidence suggesting that TG-lowering with icosapent ethyl may help stabilize high-risk plaque characteristics [36].”
§ Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies > Introduction > Coronary CT Angiography (CCTA)
What the sources say
- Partly supportedcites [36] Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925–32. sourceExperimental — accuracy not yet measured
The Results report reduced low-attenuation plaque with icosapent ethyl, and the Discussion links that change to plaque stabilization. But the Discussion also says plaque progression slowed without a significant between-group difference in triglyceride changes, so EVAPORATE does not establish triglyceride lowering as the mechanism. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Evidence from prospective longitudinal cohort studies and Mendelian randomization support a strong, dose-dependent relationship between LDL-C levels and ASCVD incidence [2, 3].”
§ Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies > Introduction
What the sources say
- Partly supportedcites [2] Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062. sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports a strong association in conventional Mendelian randomisation: a one-standard-deviation higher LDL-C level was associated with higher CHD risk (OR 1.66). It does not establish a dose-response across LDL-C levels or address the full range of ASCVD outcomes; after adjustment for apolipoprotein B and triglycerides, LDL-C did not retain a robust association with CHD. (LLM, conf=0.86)
- Partly supportedcites [3] Zhang Y, Pletcher MJ, Vittinghoff E, Clemons AM, Jacobs DRJ, Allen NB, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 2021;6:1406–13. sourceExperimental — accuracy not yet measured
The Discussion reports a dose-response association between cumulative LDL-C exposure and coronary heart disease (CHD) risk, and the Results show higher CHD risk across LDL-C exposure quartiles. The claim is broader than this paper’s finding: the Results report no association between the LDL-C measures and ischemic stroke, another ASCVD outcome. (LLM, conf=0.86)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
75 more claims · 36 with their cited sources checked
Create a free account to see all 129 claims and to verify the 7 references still open.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 7
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485 · cited 1×
“…daily may be considered, while the 2019 ESC/EAS dyslipidemia management guidelines emphasize measurement of non– HDL-C and apoB after LDL-C and advocate the selective use of TG-lowering strategies—including icosapent ethyl— for patients with mixed dyslipidemia or high risk patients [66–69 , 72 ].”
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“For example, the FIELD and ACCORD studies did not demon - strate significant reductions in major adverse CVD events (MACE) in the overall study populations, though subgroup analyses suggested potential benefit in patients with high TG and low HDL-C [61, 62 ].”
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Research works printed but not linked: 2
- 16. Meeusen J, Ueda M, Nordestgaard B RA. Lipids and lipoproteins in Tietz Textbook of Laboratory Medicine. Elsevier Inc.; 2021.
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England). 2005;366:1267–78.
Cited by
Casu, G., Idini, C., Santoru, A., Serra, G., Bilotta, F., Poddighe, C., Merella, P., Murtas, V. D., Rubbino, F., Micheluzzi, V., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104820
Rehman, M. A., Oduoye, M. O., Ozoemena, D. J., Danso, E. A., Chukwuka, G., & Odelade, M. A. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1911458
Metadata
- Authors
- Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., Bhatt, D. L., & Slipczuk, L.
- Affiliations
- Albert Einstein College of Medicine (US)
- Beth Israel Deaconess Medical Center (US)
- McGill University Health Centre (CA)
- Aga Khan University (PK)
- Johns Hopkins University (US)
- Wake Forest University Health Sciences (US)
- The University of Queensland (AU)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Slipczuk, Leandro
- ORCID
- Venue
- Current Cardiology Reports
- Published
- 2026-01-03
- Volume
- 28
- Issue
- 1
- Pages
- 8-8
- ISSN
- 1523-3782 (ISSN-L)
- 1534-3170
- PMC
- PMC12764623
- OpenAlex
- W7118079725
- Semantic Scholar
- bf3717e8194ad040108a2697e4591ed574df9372
- Cited by
- 4
- References
- 94
- Citations by year
- 2026: 4
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Cardiology Reports (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- eCommons - AKU (Aga Khan University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglycerides, triglyceride-rich lipoproteins, remnant lipoproteins, cardiovascular disease prevention, atherosclerotic cardiovascular disease, residual cardiovascular risk, apolipoprotein B, ANGPTL3 inhibitors, triglyceride-lowering therapy, diabetes mellitus, metabolic syndrome, chronic kidney disease
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Humans, Lipoproteins, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies. https://app.cochat.ai/papers/10.1007/s11886-025-02337-1
- The paper
- Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., Bhatt, D. L., & Slipczuk, L. (2026). Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies. Current Cardiology Reports. https://doi.org/10.1007/s11886-025-02337-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.